Pharmaceuticals

Short-Acting Insulin Market Insights On Growth Drivers, Trends, And Opportunities

May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Short-Acting Insulin Market Projected To Reach By 2030?

The short-acting insulin market has witnessed significant expansion in recent years. Its valuation is projected to increase from $11.54 billion in 2025 to $12.14 billion in 2026, growing at a compound annual growth rate (CAGR) of 5.3%. Historically, this growth has been influenced by the high prevalence of diabetes, widespread insulin therapy adoption, hospital-based diabetes management, expansion of insulin access programs, and improved diabetes diagnosis rates.

The short-acting insulin market is projected to experience substantial expansion in the coming years. By 2030, its valuation is predicted to reach $14.87 billion, demonstrating a compound annual growth rate (CAGR) of 5.2%. This expansion during the projected timeframe is primarily driven by factors such as the increasing prevalence of type 2 diabetes, a growing reliance on insulin, the proliferation of home-based diabetes management, advancements in insulin delivery systems, and a heightened need for fast-acting insulin. Key developments anticipated within this period encompass an escalating requirement for managing post-meal blood glucose, the wider application of rapid-acting insulin analogues, increased preference for pre-filled insulin pens, the broadening of intensive insulin therapy protocols, and a stronger emphasis on precise glycemic control.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21287&type=smp

Which Major Drivers Are Influencing The Expansion Of The Short-Acting Insulin Market?

The rising occurrence of type 1 diabetes is anticipated to propel the expansion of the short-acting insulin market in the future. This autoimmune disorder involves the body’s destruction of insulin-producing cells, necessitating continuous insulin treatment. Its growing incidence is influenced by genetic predispositions, environmental factors, and an uptick in autoimmune conditions. Short-acting insulin assists in managing type 1 diabetes through quick regulation of blood sugar and by imitating the body’s natural insulin function. For example, as reported in December 2023 by Diabetes Australia, an organization based in Australia dedicated to raising diabetes awareness, roughly 134,000 Australians had Type 1 diabetes in 2022. By 2023, this number had climbed to 135,423. Consequently, the expanding presence of type 1 diabetes is a significant force behind the growth of the short-acting insulin market.

What Are The Key Segment Divisions In The Short-Acting Insulin Market Segment Structure?

The short-acting insulin market covered in this report is segmented –

1) By Formulation: Regular Insulin, Rapid-Acting Insulin

2) By Dosage Form: Vials, Pre-filled Pens, Cartridges

3) By Route Of Administration: Subcutaneous, Intravenous

4) By Patient Type: Type 1 Diabetes, Type 2 Diabetes

5) By Distribution Channel: Pharmacies, Hospital Pharmacies, Online Pharmacies

Subsegments:

1) By Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin

2) By Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, Insulin Glulisine

What Trends Are Transforming The Short-Acting Insulin Market?

Leading companies active in the short-acting insulin market are concentrating on innovative products, such as interchangeable rapid-acting insulin biologics, to improve glycemic management and provide flexible substitution options for patients with diabetes. An interchangeable rapid-acting insulin biologic refers to a biologically derived insulin formulation designed to quickly reduce blood glucose levels following meals, which has received regulatory approval to be substituted for another equivalent insulin product without the need for a new prescription, thereby offering versatility in diabetes care and maintaining consistent glycemic control. For instance, in July 2025, Biocon Biologics, a US-based biosimilars company with headquarters in India and the U.S., secured FDA approval for Kirsty (insulin aspart xjhz), which is the first and only interchangeable rapid-acting insulin aspart available in the United States. Kirsty is recognized as a biosimilar to NovoLog (insulin aspart), with clinical and analytical data confirming no significant differences in terms of safety, efficacy, purity, and potency. It is supplied as a 100 units/mL formulation in both a single-patient-use prefilled pen (for subcutaneous use) and a multi-dose vial (for both subcutaneous and intravenous administration), aiming to enhance glycemic control in adults and children affected by diabetes mellitus.

Which Organizations Are Engaged In The Short-Acting Insulin Market?

Major companies operating in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Biocon Limited, Lupin Limited, Wockhardt Ltd., Julphar (Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., Gan & Lee Pharmaceuticals Co. Ltd., Lannett Company Inc., MannKind Corporation, ADOCIA S.A.S., Baxter International Inc., Tonghua Dongbao Pharmaceutical Co. Ltd., United Laboratories International Holdings Ltd., Bharat Biotech International Ltd., Shanghai Fosun Pharmaceutical Group Co. Ltd., Dongbao Enterprise Group Co. Ltd., Aspen Pharmacare Holdings Limited

Get The Full Short-Acting Insulin Market Report:

https://www.thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report

Where Is The Short-Acting Insulin Market Primarily Concentrated By Region?

North America was the largest region in the short-acting insulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short-acting insulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Short-Acting Insulin Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report

Browse Through More Reports Similar to the Global Short-Acting Insulin Market 2026, By The Business Research Company

Insuman Market Report 2026

https://www.thebusinessresearchcompany.com/report/insuman-global-market-report

Instant Tea Premix Market Report 2026

https://www.thebusinessresearchcompany.com/report/instant-tea-premix-global-market-report

Technical Insulation Market Report 2026

https://www.thebusinessresearchcompany.com/report/technical-insulation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795